8-K: Aprea Therapeutics Secures $3.1M Private Placement

Aprea Therapeutics, a clinical-stage biopharmaceutical company, announced a $3.1 million private placement of common stock and warrants with new and existing healthcare-focused investors and company insiders.

Summary

• Aprea Therapeutics, Inc. entered into a securities purchase agreement on December 8, 2025, for a private placement with accredited investors and company insiders.
• The company agreed to issue and sell 2,623,023 shares of common stock (or pre-funded warrants in lieu thereof) and common stock purchase warrants to acquire up to 2,623,023 shares.
• The combined effective offering price for each share (or pre-funded warrant) and accompanying common warrant is $1.165.
• The common warrants have an exercise price of $1.04 per share, are exercisable immediately upon issuance, and expire on the five-year anniversary of the earlier of the registration statement effectiveness or Rule 144 eligibility.
• Pre-funded warrants have a nominal exercise price of $0.0001 per share and are exercisable from the date of issuance until exercised in full.
• The aggregate gross proceeds from the private placement are estimated to be approximately $3.1 million.
• Maxim Group LLC acted as the sole placement agent, receiving a cash fee of 7% of the gross cash proceeds (approximately $217,000) and warrants to purchase up to 257,510 shares (5% of total securities sold).
• The company will reimburse Maxim Group LLC for reasonable expenses up to $35,000.
• The closing of the private placement is expected to occur on December 10, 2025.
• A registration statement for the resale of the securities purchased in the private placement is to be filed with the SEC on or prior to the 20th day after the closing date, with a target effectiveness date of the 45th day (or 90th day if subject to full SEC review).
• The company is subject to restrictions on issuing certain equity securities or engaging in variable rate transactions for 120 to 180 days following the effectiveness date of the registration statement, with customary exceptions.

Sentiment

Score: 6

Explanation: The private placement provides necessary capital and extends the cash runway, which is positive for a clinical-stage company. However, it involves significant dilution and standard restrictions on future financing, reflecting a neutral to slightly positive outlook given the context of biotech funding needs.

Positives

• The private placement secured approximately $3.1 million in gross proceeds, providing capital for operations.
• The company expects the net proceeds to extend its cash runway into Q1 2027, offering financial stability for ongoing clinical programs.
• Participation from both new and existing healthcare-focused investors, as well as company insiders, indicates continued investor confidence.
• The warrants issued do not include Black Scholes cash payment obligations, price protection anti-dilution, or price reset provisions, which can be favorable for the company by avoiding future downward adjustments to the exercise price (other than standard pro rata adjustments).

Negatives

• The issuance of 2,623,023 shares (or pre-funded warrants) and warrants for an additional 2,623,023 shares will result in significant dilution for existing shareholders.
• Placement agent fees (7% cash fee and 5% warrant coverage) and expenses (up to $35,000) will reduce the net proceeds received by the company.
• Restrictions on future equity issuances for 120 to 180 days post-registration statement effectiveness could limit the company's flexibility to raise additional capital quickly if needed, outside of specified exceptions.

Risks

• The securities offered and sold in the private placement are unregistered and may not be reoffered or resold without an effective registration statement or an applicable exemption from registration.
• Holders of warrants are subject to beneficial ownership limitations (4.99% or 9.99%) which restrict the number of shares they can acquire upon exercise.
• Past or future open market or derivative transactions by purchasers, including Short Sales, may negatively impact the market price of the company's publicly-traded securities.
• Failure to timely file or achieve effectiveness of the resale registration statement could result in liquidated damages payable to the purchasers.
• The company must maintain its Nasdaq listing and comply with listing requirements, with potential risks of delisting if not met.
• General risks inherent to clinical-stage biopharmaceutical companies, including the uncertainties of research and development, clinical trial outcomes, regulatory approvals, and market acceptance of products.

Future Outlook

The company anticipates that the aggregate net proceeds from this private placement will be sufficient to fund its operations into the first quarter of 2027. During this period, Aprea Therapeutics expects to reach potential inflection points in its clinical programs, which are focused on developing treatments for various cancer types.

Management Comments

• The proceeds are expected to extend the Company’s cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that period.

Industry Context

This private placement is a typical financing mechanism for clinical-stage biopharmaceutical companies like Aprea Therapeutics, which often rely on external capital to fund extensive and costly research and development efforts. The 'at-the-market' pricing, as per Nasdaq rules, suggests the offering was structured to align with current market valuations, a common practice to facilitate investor participation. The involvement of healthcare-focused investors underscores the specialized nature of biotech funding, where investors often have a deep understanding of the industry's risks and potential rewards. The extension of the cash runway is a critical outcome for such companies, providing necessary time to advance clinical trials and potentially achieve key milestones.

Comparison to Industry Standards

• The 7% cash fee and 5% warrant coverage for the placement agent are consistent with industry standards for private placements in the biopharmaceutical sector, particularly for offerings of this size.
• The exercise price of $1.04 for the common warrants, relative to the combined offering price of $1.165, provides a standard incentive for investors, reflecting a common structure in such equity-linked financings.
• The use of pre-funded warrants with a nominal exercise price is a common strategy to allow investors to participate fully in the offering while managing beneficial ownership limitations, a frequent concern in private placements.
• The inclusion of a 120-day restriction on certain equity issuances and a 180-day restriction on Variable Rate Transactions is a customary protective covenant for investors in private placements, aiming to prevent immediate further dilution or unfavorable financing terms.

Related Party Transactions

• Certain company insiders are participating as purchasers in the private placement.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new shares and warrants. However, the financing extends the company's cash runway, which could be seen as positive for long-term stability and continued R&D.
• Investors (Purchasers): New and existing healthcare-focused investors and company insiders are acquiring securities at an 'at-the-market' price, with warrants providing potential upside, subject to exercise and market performance.
• Employees: The extended cash runway provides greater financial stability for ongoing operations and research and development efforts, potentially securing employment and project continuity.

Next Steps

• The private placement is expected to close on or about December 10, 2025, subject to customary closing conditions.
• The company is obligated to file a registration statement for the resale of the securities purchased in the private placement on or prior to the 20th day after the closing date.
• Aprea Therapeutics will use reasonable best efforts to cause the registration statement to be declared effective as promptly as practicable, but no later than the 45th day after the closing date (or 90th day if subject to full SEC review).
• The company anticipates potential inflection points in its clinical programs during the period covered by the extended cash runway (into Q1 2027).

Key Dates

Recommendation

The private placement is a necessary capital infusion for Aprea Therapeutics, extending its cash runway into Q1 2027 and allowing continued clinical development. While the 'at-the-market' pricing and insider participation offer some reassurance, the significant dilution from the issuance of new shares and warrants, coupled with the inherent high risks of clinical-stage biopharmaceutical development, warrants a 'hold' recommendation. Investors should monitor the progress of the company's clinical programs and future financing needs closely, as these will be key drivers of long-term value.

Keywords

Aprea Therapeutics, APRE, Private Placement, Equity Financing, Warrants, Pre-Funded Warrants, Common Stock, SEC Filing, Form 8-K, Biopharmaceutical, Clinical-stage, Capital Raise, Nasdaq, Maxim Group LLC, Registration Rights, Dilution